Early trial of SynKIR-110 for certain ovarian and lung-lining cancers
Part of Cancer, Hormones & metabolism, Lungs & breathing, Women’s health & pregnancy clinical trials.
This Phase 1 study tests SynKIR-110 in people with certain advanced cancers that have come back or continued growing after prior treatments. It aims to find out if the treatment is safe and how the body responds, including early signs of effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one of these cancers: ovarian cancer, primary peritoneal cancer, fallopian tube cancer, cholangiocarcinoma, or epithelial mesothelioma, and it is advanced and has returned after at least one prior treatment
- You are 18 years old or older
- Your current health/energy is good (ECOG 0 to 1, meaning you are able to do most activities or only limited activity)
- Scans show at least one measurable spot that can be followed during the trial
- Your blood clotting, kidney/liver function, and bone marrow tests are within allowed limits
- You do NOT have certain other conditions like other active cancers, certain past immune-cell (T-cell) treatments, or uncontrolled infections/immune issues
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SY001, which targets a protein called mesothelin found on some cancer cells. It is designed for people with advanced ovarian or pancreatic cancer who have already tried other treatments and whose tumor tissue has mesothelin.
This trial tests a new treatment called KT032, which are special immune cells (CAR-T cells) designed to attack cancer cells that have a protein called mesothelin. It is for people with advanced solid tumors, especially those that have spread to the abdomen, who have run out of standard options.
This trial tests a new type of immune cell therapy (CIML NK cells) given directly into the abdomen for women with ovarian cancer that has come back and is now resistant to standard platinum chemotherapy. The goal is to see if these specially trained cells can fight the cancer safely.
This trial tests a new treatment called SynKIR-310 for people with B-cell non-Hodgkin lymphoma whose cancer has come back or not responded to at least 2 prior treatments. It may be an option if you've already had CAR T-cell therapy or cannot have it.
This early-phase study tests SZ011 in people with ovarian epithelial cancer that has come back or did not respond to standard first treatment. You may qualify if your tumor shows a specific marker (mesothelin) and your health tests are strong enough to safely receive the study drug.
This trial tests a new cell therapy called YK1101 for people with advanced solid tumors that have not responded to standard treatment. It targets a specific protein (MAGE-A4) on cancer cells and requires a matching genetic type called HLA-A*11:01.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.